bioAffinity Technologies: Lung Cancer Detection Breakthrough

bioAffinity Technologies, Inc. (BIAF) has been making waves in the biotechnology sector with its innovative, noninvasive test for early-stage lung cancer detection, CyPath® Lung. The company's commitment to improving patient outcomes through groundbreaking diagnostics has led to a significant boost in sales and market expansion.

CyPath® Lung uses advanced flow cytometry and artificial intelligence (AI) to identify cell populations in patient sputum that indicate malignancy. The test has demonstrated high sensitivity, specificity, and accuracy in detecting lung cancer in patients at high risk for the disease. With a 92% sensitivity rate, 87% specificity, and 88% accuracy, CyPath® Lung has proven to be a valuable tool in early lung cancer detection.

The company's strategic approach to marketing and sales has contributed to the growing adoption of CyPath® Lung. The introduction of a reimbursement code for the test has made it more accessible to physicians, driving a 375% increase in tests ordered and processed over the past three months. Additionally, the completion of branding efforts and the expansion of the sales force have further fueled physician interest and adoption of the innovative test.



bioAffinity Technologies' success can also be attributed to strategic acquisitions and partnerships. The acquisition of Precision Pathology Laboratory Services (PPLS) in September 2023 resulted in a 20% increase in annualized revenues over 2023, with CyPath® Lung sales surging 1,750% compared to the same period last year. Furthermore, the company's inclusion in the U.S. Federal Supply Schedule (FSS) in October 2024 provided streamlined access to state-of-the-art healthcare products and services for the Veterans Health Administration and the Military Health System, significantly expanding the reach of CyPath® Lung.



Physician referrals and word-of-mouth, particularly from key opinion leaders (KOLs), have also played a crucial role in driving the expansion of CyPath® Lung across multiple states. In Q3 2024, bioAffinity Technologies reported a 75% increase in the number of physician offices signed compared to Q2 2024, with orders now coming from 11 states, up from 8 in the previous quarter.

The company's focus on expanding its operations and strengthening its foothold in the rapidly growing lung cancer diagnostics market has positioned it for continued success. With a strong sales and support infrastructure in place, bioAffinity Technologies is well-equipped to meet rising demand and accelerate its nationwide growth.

In conclusion, bioAffinity Technologies' innovative CyPath® Lung test, strategic marketing efforts, and strategic acquisitions have contributed to its remarkable sales growth and market expansion. As the company continues to advance its mission to enhance patient outcomes through groundbreaking, noninvasive cancer diagnostics, investors should keep a close eye on its progress in the lung cancer diagnostics market.